NASDAQ NMS - GLOBAL MARKET · QURE
+2.16% · +$0.9800 · Vol 1.8M
Market closed · last close 4:00 PM ET · price as of 16:19:16 ET
Uniqure NV

Uniqure NV

Biotechnology
$46.34
Card
Relationship Map

Veridion Score

BETALOW CONF · 5/6 factorsMethodology
QURE
Uniqure NV
Sat Aug 8 · market closed · Markets closed · resumes Mon 9:30 ET
NEUTRAL

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
NEUTRAL · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5/6 factors with data · Sat Aug 8 · market closed · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is QURE moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading QURE catalysts
About Uniqure NV
PHARMACEUTICAL PREPARATIONS
Listed since
2014
Employees
221
Country
NL

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$46.59
Day high
$48.10
Day low
$45.02
Previous close
$45.36
52W high
$70.59
-34.35% from high
52W low
$9.03
61% of range
Market cap
$3.2B
EPS
$-4.1400
Beta
-0.86
Shares out
69.4M
Volume
1.8M
1.14× rel vol
Avg volume
1.6M
VWAP
$46.39
Price history computed in-house
1W
+6.21%
1M
+4.18%
3M
+67.53%
1Y
+248.95%
YTD
+93.65%
SMA 50 $38.71 · above
SMA 200 $28.14 · above
52W position 61%

QURE overview

Veridion Score
59
5 of 6 factors measured
Congress receipts
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around QURE.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading QURE Form 4 filings
Public disclosures

Congress activity in QURE

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for QURE in the cached public ledger.

Federal contracts

QURE contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for QURE in this window.
Lobbying spend

QURE lobbying filings, year to date.

Registered lobbying filings matched to Uniqure NV.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for QURE in this window.
Loading news for QURE
Analyst ratings
Sovereign unlock shows live analyst consensus for QURE.
Options
Sovereign unlock shows live options positioning for QURE.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.